Subsequent to publication of this paper errors in [Table 5](#T5){ref-type="table"} (solicited local and systemic adverse events...) have come to light. Below is the revised table.

###### **Table 5** Solicited local and systemic adverse events reported within five days of each vaccination in the Core Study and Booster Phase based on the safety population

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            Core study n (%) \[95% CI\]^a^   Booster phase n (%) \[95% CI\]^a^                                                                                                                               
  ------------------------- -------------------------------- ----------------------------------- --------------- --------------- --------------------------------------------- --------------------------------------------- ---------------
  Adverse events            Lot A\                           Lot B\                              Lot C\          Pooled\         Booster plus Rouvax (concomitantly) N = 105   Booster plus Rouvax (1 month later) N = 110   Pooled\
                            N = 119                          N = 120                             N = 121         N = 360                                                                                                     N = 215

  Local                                                                                                                                                                                                                       

  Induration                21 (17.6)\                       29 (24.2)\                          31 (25.6)\      81 (22.5)\      25 (23.8)\                                    24 (21.8)\                                    49 (22.8)\
                            \[11.3,25.7\]                    \[16.8,32.8\]                       \[18.1,34.4\]   \[18.3,27.2\]   \[16.0,33.1\]                                 \[14.5,30.7\]                                 \[17.4,29.0\]

  Systemic                                                                                                                                                                                                                    

  ≥ 1 event reported        96 (80.7)\                       96 (80.0)\                          83 (68.6)\      275 (76.4)\     69 (65.7)\                                    60 (54.5)\                                    129 (60.0)\
                            \[72.4,87.3\]                    \[71.7,86.7\]                       \[59.5,76.7\]   \[71.7,80.7\]   \[55.8,74.7\]                                 \[44.8,64.1\]                                 \[53.1,66.6\]

  Fever^b^                  44 (37.0)\                       41(34.2)\                           38 (31.4)\      123(34.2)\      20 (19.0)\                                    16 (14.5)\                                    36 (16.7)\
                            \[28.3,46.3\]                    \[28.8,43.4\]                       \[23.3,40.5\]   \[29.3,39.3\]   \[12.0,27.9\]                                 \[8.5,22.5\]                                  \[12.0,22.4\]

  Rash                      28 (23.5)\                       31 (25.8)\                          29 (24.0)\      88(24.4)\       5 (4.8)\                                      10 (9.1)\                                     15 (7.0)\
                            \[16.2,32.2\]                    \[18.3,34.6\]                       \[16.7,32.6\]   \[20.1,29.2\]   \[1.6,10.8\]                                  \[4.4,16.1\]                                  \[4.0,11.2\]

  Change in eating habits   28 (23.5)\                       32 (26.7)\                          34 (28.1)\      94(26.1)\       30 (28.6)\                                    27 (24.5)\                                    57 (26.5)\
                            \[16.2,32.2\]                    \[19.0,35.5\]                       \[20.3,37.0\]   \[21.6,31.0\]   \[20.2,38.2\]                                 \[16.8,33.7\]                                 \[20.7,32.9\]

  Sleepiness                47 (39.5)\                       45 (37.5)\                          44 (36.4)\      136(37.8)\      29 (27.6)\                                    26 (23.6)\                                    55 (25.6)\
                            \[30.7,48.9\]                    \[28.8,46.8\]                       \[27.8,45.6\]   \[32.7,43.0\]   \[19.3,37.2\]                                 \[16.1,32.7\]                                 \[19.9,32.0\]

  Unusual crying            55 (46.2)\                       59 (49.2)\                          51 (42.1)\      165(45.8)\      35 (33.3)\                                    31 (28.2)\                                    66 (30.7)\
                            \[37.0,55.6\]                    \[39.9,58.4\]                       \[33.2,51.5\]   \[40.6,51.1\]   \[24.4,43.2\]                                 \[20.0,37.6\]                                 \[24.6,37.3\]

  Persistent crying         13 (10.9)\                       11 (9.2)\                           10 (8.3)\       34(9.4)\        2 (1.9)\                                      2 (1.8)\                                      4 (1.9)\
                            \[5.9,18.0\]                     \[4.7,15.8\]                        \[4.0,14.7\]    \[6.6,12.9\]    \[0.2,6.7\]                                   \[0.2,6.4\]                                   \[0.5,4.7\]

  Irritability              42 (35.3)\                       39 (32.5)\                          34 (28.1)\      115(31.9)\      28 (26.7)\                                    21 (19.1)\                                    49 (22.8)\
                            \[26.8,44.6\]                    \[24.2,41.7\]                       \[20.3,37.0\]   \[27.2,37.0\]   \[18.5,36.2\]                                 \[12.2,27.7\]                                 \[17.4,29.0\]

  Vomiting                  28 (23.5)\                       30 (25.0)\                          26 (21.5)\      84(23.3)\       10 (9.5)\                                     5 (4.5)\                                      15 (7.0)\
                            \[16.2,32.2\]                    \[17.5,33.7\]                       \[14.5,29.9\]   \[19.1,28.1\]   \[4.7,16.8\]                                  \[1.5,10.3\]                                  \[4.0,11.2\]

  Diarrhea                  20 (16.8)\                       27 (22.5)\                          23 (19.0)\      70(19.4)\       8 (7.6)\                                      11 (10.0)\                                    19 (8.8)\
                            \[10.6,24.8\]                    \[15.4,31.0\]                       \[12.4,27.1\]   \[15.5,23.9\]   \[3.3,14.5\]                                  \[5.1,17.2\]                                  \[5.4,13.5\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Values (%) based on number of infants experiencing an event/total number of infants receiving at least one injection (N). ^b^Fever defined as body temperature ≥ 38.0 °C. N = total number of infants receiving at least one injection (i.e. safety population). All local adverse events were considered vaccination-related; values for systemic adverse events represent all solicited adverse events reported, regardless of whether or not they were considered vaccination-related
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